Ultragenyx PharmaceuticalRARE
Recorded

Ultragenyx Pharmaceutical Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Maury RaycroftBiotech Analyst

Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I am happy to welcome the team from Ultragenyx. We have Emil Kakkis, the CEO, and Howard Horn, the Chief Financial Officer. Thanks so much for joining us today.

Emil KakkisCEO

Happy to be here. Thanks, Maury.

Maury RaycroftBiotech Analyst

We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to Ultragenyx.

Emil KakkisCEO

Sure. Ultragenyx is a company working on rare and ultra-rare disease treatments. We have been on the public markets for 12 years, and we have six approved programs in that time, including two gene therapies, monoclonal antibody, enzyme, and small molecule treatments for a variety of rare and ultra-rare diseases. We work in bone, endocrine, neuro, and also in inborn errors of metabolism. We are a diversified global company. We have commercial operations in North America, South America, Europe, Middle East, and Japan. We believe in exploring the full global markets as a way to build our business. Our base business of four original products have been growing at around 20% a year for the last few years, and we just added two new gene therapy approvals, which we can talk more about. They are launching now. With those approvals, we also got two PRVs.

Emil KakkisCEO

We had a program, Angelman treatment for GTX-102, that did miss recently, which led to a need for cost containment and controls, which we have implemented, which put us on track to be next year a profitable company. We expect to be $1 billion plus in revenue, and to be meaningfully profitable, and to be able to operate a more narrowed, focused R&D footprint going forward. We are excited about this next stage of getting to profitability, which was, I think, our original plan. We continue to work on an R&D platform which will generate appropriate upside, but we are also being driven by our commercial franchise. We can talk more about the launches and the other programs as we get through.

Maury RaycroftBiotech Analyst

Yeah. Yeah, I think that is a great intro, a lot to talk about. Maybe starting first with commercial and profitability, you have reiterated the GAAP profitability and positive operating cash flow in 2027. Can you walk us through the major assumptions underpinning that guidance? When we talk about the base business growth contributions from GENGLYCOS and FAYUVI, and the level of pipeline investment, particularly if setrusumab requires additional development.

Emil KakkisCEO

Yeah, I think I would just start by saying that we always had a plan to become profitable. In this case, we need to do it at that moment in time without an Angelman revenue source. But we had enough revenue to base it, and we could right-size our development organization and get us there, and to meaningful profitability. But I will let Howard put together some of the pieces of that story, since he has been intimately helping putting that together.

Howard HornCFO

Maury, you are right. We have guided to full-year GAAP profitability in 2027. We also said positive cash from operations. That is a real turning point for the company. The assumptions to get there are that the current four programs continue to grow. As Emil mentioned, they have been growing well for many years. Then some supplementation from the two gene therapy launches to build the top line. Then we had recently given guidance on R&D and SG&A, where we talked about ceilings of $350 million next year for R&D and a ceiling of $375 million next year for SG&A. Those are the building blocks of it.

Maury RaycroftBiotech Analyst

Got it. Yeah, that makes sense. Maybe starting with the expense guidance there, you are saying those are ceilings, so that implies the floor could be lower. I guess, what can you say about those ranges then?

Howard HornCFO

At this point, we have just commented on the ceiling part of it. But what we really wanted to do is give people comfort that we had turned the corner, and I hope that came through.

Maury RaycroftBiotech Analyst

Or some of the levers that could potentially get you lower on expenses too.

Howard HornCFO

Yeah. The, yeah, obviously, if you choose not to do a program or you choose not to go into a region or expand something, or if you chose to reduce on spend. It is all the normal levers.

Maury RaycroftBiotech Analyst

Yeah. Okay. Okay, and for CRYSVITA, third quarter revenues came in at $109 million. How much of the shortfall was North American shipment timing and other technical issues versus true underlying demand? What are you seeing in fourth quarter so far that gives you confidence in the strong rebound of about $142 million-$162 million?

Howard HornCFO

Yeah, I think importantly, we give full-year guidance, and we, at the outset of the year, said for CRYSVITA, $500 million-$520 million, and we have reiterated that each quarter, and we did so again in our third quarter call. We feel good about the full-year part of it. Maybe what you are asking is, we talked about a sawtooth pattern that goes through the four quarters of the year, and that is driven by ordering patterns in some regions and seasonality in others, and we followed that pattern.

Howard HornCFO

Yeah The concept of a shortfall is not the way I would think of it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day